National Center for Tumor Diseases (NCT) Heidelberg Revenue and Competitors

Heidelberg, Germany

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • National Center for Tumor Diseases (NCT) Heidelberg's estimated annual revenue is currently $58.2M per year.(i)
  • National Center for Tumor Diseases (NCT) Heidelberg's estimated revenue per employee is $297,000

Employee Data

  • National Center for Tumor Diseases (NCT) Heidelberg has 196 Employees.(i)
  • National Center for Tumor Diseases (NCT) Heidelberg grew their employee count by 13% last year.

National Center for Tumor Diseases (NCT) Heidelberg's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$21.6M80-10%N/AN/A
#2
$42.5M1438%N/AN/A
#3
$161M4771%N/AN/A
#4
$58.2M19613%N/AN/A
#5
$30M11118%N/AN/A
#6
$128.6M381-24%N/AN/A
#7
$26.5M9838%N/AN/A
#8
$50.2M169-2%N/AN/A
#9
$296M78310%N/AN/A
#10
$27.8M103-6%N/AN/A
Add Company

What Is National Center for Tumor Diseases (NCT) Heidelberg?

The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.

keywords:N/A

N/A

Total Funding

196

Number of Employees

$58.2M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

National Center for Tumor Diseases (NCT) Heidelberg News

2022-04-19 - Reprogrammed macrophages promote spread of breast cancer

Metastatic breast cancer cells abuse macrophages, a type of immune cell, ... the National Center for Tumor Diseases (NCT) in Heidelberg and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.4M21524%N/A
#2
$38.9M244N/AN/A
#3
$39.2M2747%N/A
#4
$86.4M3298%N/A
#5
$106.6M60920%N/A